Literature DB >> 22866110

Prolonged survival in advanced thymoma: Effectiveness of sequential multiple lines of chemotherapy in an inoperable case.

Manuela Bergonzi1, Giulio Orlandoni, Franco Corbella, Paolo G Gobbi.   

Abstract

A standard therapeutic approach for advanced malignant thymoma has yet to be defined given the rarity of this condition. We present a patient with advanced thymoma, evaluated as inoperable at diagnosis due to multiple serosal metastases. The strong constitution and determination of the patient allowed treatment with six distinct and subsequent chemotherapy regimens, all administered on an outpatient basis. A survival of 64 months from diagnosis was achieved. A favorable clinical response was obtained after the first three treatment lines, with the disappearance of all lesions on both computed tomography and positron emission tomography (PET) images. However, this result was not confirmed by surgical exploration of the thorax, undertaken with the aim of radical excision of possible residual disease. The presence of multiple pleural nodules, not evident on the imaging techniques, prevented even limited tumor debulking. The chemotherapy lines administered following detection of the lessions, stabilized the disease for a further 2 years, while a satisfactory quality of life was maintained. Only in the last months did the tumor progress and signs of cardiotoxicity appear, with the latter constituting the eventual cause of death. This case is important since the medical literature does not indicate non-cross-resistant regimens for advanced thymoma following second-line chemotherapy, and the sequence of regimens presented in this case study may serve as a feasible outline program. Moreover, we highlight the known possibility of false-negative PET studies, which can occur despite the claimed glucose avidity of thymoma tissue.

Entities:  

Year:  2011        PMID: 22866110      PMCID: PMC3410454          DOI: 10.3892/ol.2011.282

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  10 in total

1.  PET: other thoracic malignancies.

Authors:  Leslie E Quint
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma.

Authors:  Tetsuya Oguri; Hiroyuki Achiwa; Daisuke Kato; Hiroyoshi Maeda; Takashi Niimi; Shigeki Sato; Ryuzo Ueda
Journal:  Chemotherapy       Date:  2004-12-08       Impact factor: 2.544

3.  18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.

Authors:  Yon Mi Sung; Kyung Soo Lee; Byung-Tae Kim; Joon Young Choi; Young Mog Shim; Chin A Yi
Journal:  J Nucl Med       Date:  2006-10       Impact factor: 10.057

4.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.

Authors:  P J Loehrer; M Jiroutek; S Aisner; J Aisner; M Green; C R Thomas; R Livingston; D H Johnson
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

Review 5.  Multimodality treatment of thymic tumors.

Authors:  Federico Venuta; Erino A Rendina; Giorgio F Coloni
Journal:  Thorac Surg Clin       Date:  2009-02       Impact factor: 1.750

6.  Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.

Authors:  Edward S Kim; Joe B Putnam; Ritsuko Komaki; Garrett L Walsh; Jae Y Ro; Hyung Ju Shin; Mylene Truong; Hojin Moon; Steven G Swisher; Frank V Fossella; Fadlo R Khuri; Waun K Hong; Dong M Shin
Journal:  Lung Cancer       Date:  2004-06       Impact factor: 5.705

Review 7.  Prognostic factors for thymic epithelial neoplasms, with emphasis on tumor staging.

Authors:  Mark R Wick
Journal:  Hematol Oncol Clin North Am       Date:  2008-06       Impact factor: 3.722

Review 8.  Optimal therapy for thymoma.

Authors:  Kazuya Kondo
Journal:  J Med Invest       Date:  2008-02

Review 9.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

10.  Long-term survival and prognostic factors in thymic epithelial tumours.

Authors:  Federico Rea; Giuseppe Marulli; Rodolfo Girardi; Luigi Bortolotti; Adolfo Favaretto; Alessandra Galligioni; Francesco Sartori
Journal:  Eur J Cardiothorac Surg       Date:  2004-08       Impact factor: 4.191

  10 in total
  1 in total

1.  Rarity among the rare-large and invasive thymoma, a case report and review.

Authors:  Khadija Tayabali; Hussein Pothiwalla; Jason Thole; Binh Nguyen
Journal:  J Community Hosp Intern Med Perspect       Date:  2020-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.